Esperion Therapeutics Stock News

ESPR earnings call for the period ending December 31, 2021.

Esperion Therapeutics, Inc. (ESPR) CEO Sheldon Koenig on Q4 2021 Results - Earnings Call Transcript

Esperion Therapeutics (NASDAQ: ESPR ) reported its Q4 earnings results on Tuesday, February 22, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Esperion Therapeutics beat estimated earnings by 22.03%, reporting an EPS of $-1.77 versus Full story available on Benzinga.com

Esperion Therapeutics press release (ESPR): Q4 GAAP EPS of -$1.77 beats by $0.52.Revenue of $15.4M (+59.8% Y/Y) beats by $0.92M.As of December 31, 2021, cash, cash

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 23.71% and 6.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock

Companies Reporting Before The Bell Gaotu Techedu (NYSE: GOTU ) is projected to report quarterly earnings at $0.13 per share on revenue of $439.63 million. Sohu.com (NASDAQ: SOHU ) is expected to report earnings for its fourth quarter. Kiniksa Pharmaceuticals (NASDAQ: KNSA ) is likely to report quarterly loss at $0.42 per share on revenue of $20.72 million. Hecla Mining (NYSE: HL ) is expected to report quarterly earnings at $0.02 per share on revenue of $198.95 million. Standard Motor Products (NYSE: SMP ) is expected to report quarterly earnings at $0.67 per share on revenue of $282.91 million. KBR (NYSE: KBR ) is likely to report quarterly earnings at $0.65 per share on revenue of $2.53 billion. Fresenius Medical Care (NYSE: FMS ) is likely to report quarterly earnings at $0.49 per share on revenue of $5.22 billion. Ardagh Metal Packaging (NYSE: AMBP ) is expected to report quarterly earnings at $0.09 per share on revenue of $1.02 billion. Krispy Kreme (NASDAQ: DNUT ) is estimated to report quarterly earnings at $0.

Esperion Therapeutics (NASDAQ:ESPR) is scheduled to announce Q4 earnings results on Tuesday, February 22nd, before market open.The consensus EPS Estimate is -$2.29 and the consensus…

Esperion Therapeutics, Inc. (NASDAQ:ESPR) with the stream of -4.20% also noticed, India Galiano Gold Inc. (AMEX:GAU) encountered a rapid change of 1.59% in the last hour of Mondays trading session. The post Beholding Stock: Esperion Therapeutics, Inc. (NASDAQ:ESPR), Galiano Gold Inc. (AMEX:GAU) appeared first on Stocks Equity .

Esperion Therapeutics Inc. ( ESPR , Financial) calls itself the "Lipid Management Company," a pharmaceutical company focused on developing and commercializing affordable, oral, once-daily, non-statin

NEXLETOL and NEXLIZET, treatments for "bad" cholesterol, have high untapped market potential in the US.

Esperion Therapeutics continues to report lackluster growth with their NEXLETOL and NEXLIZET products. As a result, the share price continues to hit fresh all-time-lows with little-to-no signs of a re

Gainers: Bed Bath & Beyond BBBY +6%, Orphazyme (ORPH) +4%, Esperion Therapeutics ESPR +4%, Aurora Innovation (AUROW) +4%, Canadian Solar (CSIQ) +3%. Losers: Gogo

Esperion Therapeutics Inc. (ESPR) shares closed this week 22.4% lower than it did at the end of last week. The stock is currently down 19.4% year-to-date, down 87.0% over the past 12 months, and down 70.6% over the past five years. This week, the Dow Jones Industrial Average fell 1.3%, and the S&P 500 fell 2.6%. Trading Activity Shares traded as high as $5.28 and as low as $3.90 this week.Shares closed 89.8% below its 52-week high and 3.3% above its 52-week low.Trading volume this week was 1.3% higher than the 10-day average and 13.4% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 112.0% The company's stock price performance over the past 12 months lags the peer average by 1022.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.